CallAID Network


Reporting County-Level COVID-19 Vaccination Data

2019 Novel Coronavirus (CDC) - 17 hours 25 min ago
CDC's COVID Data Tracker provides county-level COVID-19 vaccination data in the United States. This site provides an integrated, county view of key data for monitoring the COVID-19 pandemic in the United States. It allows users to explore standardized data
Categories: C.D.C. (U.S.), Health

Coronavirus Disease 2019 (COVID-19)

2019 Novel Coronavirus (CDC) - 17 hours 25 min ago
Coronavirus (COVID-19) Home Page
Categories: C.D.C. (U.S.), Health

Staffing Resources

2019 Novel Coronavirus (CDC) - 17 hours 25 min ago
Federal staffing resources for health departments.
Categories: C.D.C. (U.S.), Health

Cases in the U.S.

CDC COVID Data Tracker - Cases and Deaths by State
Categories: C.D.C. (U.S.), Health

Testing Data in the U.S.

Testing in the U.S.
Categories: C.D.C. (U.S.), Health

Reporting COVID-19 Vaccinations in the United States

Information on COVID-19 vaccination data reported in CDC's COVID Data Tracker.
Categories: C.D.C. (U.S.), Health

SARS-CoV-2 Variant Classifications and Definitions

Variants of SARS-CoV-2, the virus that causes COVID-19, have been reported in many countries around the world. Learn more about the current variants of concern.
Categories: C.D.C. (U.S.), Health

COVID-19 Forecasts: Deaths

Forecasts show national and state level cumulative reported and predicted deaths since the beginning of the pandemic. CDC is working with partners to bring together weekly COVID-19 forecasts in one place.
Categories: C.D.C. (U.S.), Health

COVID-19 Forecasts: Cases

Learn about COVID-19 forecasts and modeling for new cases.
Categories: C.D.C. (U.S.), Health

Previous COVID-19 Forecasts: Hospitalizations

Learn about COVID-19 forecasts and modeling for new hospitalizations.
Categories: C.D.C. (U.S.), Health

Key Things to Know About COVID-19 Vaccines

Learn the key things you need to know about the new COVID-19 vaccines.
Categories: C.D.C. (U.S.), Health

Responder Stories

Learn about Coronavirus Disease 2019 (COVID-19), including symptoms, complications, transmission, prevention, treatment, and summary updates of the outbreak.
Categories: C.D.C. (U.S.), Health

The CDC That Never Sleeps

When Bob Briley retired as a firefighter and paramedic in West Palm Beach, FL to work with the Federal Emergency Management Agency (FEMA), he was accustomed to a 24/7 schedule with a certain level of unpredictability. He also knew that his poised under pressure temperament was an asset to his success. When he brought that skill set to CDC in 2009 as a Deployment Briefing Coordinator during H1N1, he may have solidified his path as one who works in the places that never sleep.
Categories: C.D.C. (U.S.), Health

Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)

Learn about hospital surveillance (rates) and how that information helps find who is most at risk for severe illness and death, including important demographic information
Categories: C.D.C. (U.S.), Health

Information about the Moderna COVID-19 Vaccine

The Moderna COVID-19 vaccine is an mRNA vaccine that requires 2 shots, 28 days apart. Learn about safety data, efficacy, and clinical trial demographics.
Categories: C.D.C. (U.S.), Health

Selected Adverse Events Reported after COVID-19 Vaccination

COVID-19 vaccines are safe and effective. Millions of people in the United States have received COVID-19 vaccines, and these vaccines will undergo the most intensive safety monitoring in U.S. history. CDC recommends you get a COVID-19 vaccine as soon as you are eligible. Adverse events described on this page have been reported to the Vaccine Adverse Event Reporting System (VAERS).
Categories: C.D.C. (U.S.), Health

COVID-19 Travel Recommendations by Country

Search COVID-19 risk assessment by country larger map
Categories: C.D.C. (U.S.), Health

Looking to the future: The Rockefeller Foundation and WHO identify priorities for global health collaboration

WHO news - 29.11.2021

On 8-10 November 2021, Dr Naveen Rao, Senior Vice President, Health and other senior representatives from The Rockefeller Foundation joined World Health Organization (WHO) representatives to review the strategic directions of collaboration between the two Organizations. Notably they discussed support for the WHO Health Emergencies Programme and the Science Division, including the WHO Hub on for Pandemic and Epidemic Intelligence, genomic surveillance, infodemiology, vaccine equity and demand generation and WHO’s ongoing work with philanthropic organizations.

”The Rockefeller Foundation and WHO have worked together to address global health challenges since WHO was first established,” said Ms Jane Ellison, Executive Director, External Relations and Governance. ”The support of the Foundation has been – and will continue to be - fundamental, helping WHO to make major advances in providing equitable health outcomes for all.”

The Rockefeller Foundation’s collaboration with WHO dates back to when the WHO constitution was first created. Over the past two decades, The Rockefeller Foundation has continued to be a key collaborator, providing over US$ 25.3 million in support to WHO programmes.

Recent collaboration has focused on digital health building capacity in data and innovation to protect and promote health and well-being. Throughout the COVID-19 pandemic, the two Organizations worked together towards the goal of maintaining essential health services everywhere, expanding virus testing capacity, strengthening and accelerating the digitalization of WHO guidelines, and advancing approaches to using digital products to end the current pandemic and prevent future ones. The Rockefeller Foundation and WHO currently co-lead the Access to COVID-19 Tools Accelerator (ACT-A) Genomic Surveillance Working Group.

“The Rockefeller Foundation recognizes WHO’s unique and vital role in safeguarding global health and well-being,” said Dr Naveen Rao, Senior Vice President, Health, The Rockefeller Foundation. “We remain steadfast in our commitment to support WHO to be a strong and efficient Organization.”

The overall objectives of the strategic dialogue were for the two Organizations to gain a better understanding of each other’s current work and priorities, and explore expanded areas for collaboration based on a more deliberate and forward-looking relationship leveraging the comparative advantages of each Organization to maximize public health impact.

Joint Statement on Dose Donations of COVID-19 Vaccines to African Countries

WHO news - 29.11.2021

Building on lessons learned from our collective experience with dose donations over the past several months, the African Vaccine Acquisition Trust (AVAT), the Africa Centres for Disease Control and Prevention (Africa CDC) and COVAX wish to draw the attention of the international community to the situation of donations of COVID-19 vaccines to Africa, and other COVAX participating economies, particularly those supported by the Gavi COVAX Advance Market Commitment (AMC).

AVAT and COVAX complement each other’s efforts to support African countries to meet their immunisation targets, recognising the global goal of immunising 70% of the African population. Dose donations have been an important source of supply while other sources are stepping up, but the quality of donations needs to improve.

AVAT and COVAX are focused on accelerating access to and rollout of COVID-19 vaccines in Africa. Together we are rapidly expanding supply to the continent, and providing countries with the support to be able to utilise the doses they receive. To date, over 90 million donated doses have been delivered to the continent via COVAX and AVAT and millions more via bilateral arrangements.

However, the majority of the donations to-date have been ad hoc, provided with little notice and short shelf lives. This has made it extremely challenging for countries to plan vaccination campaigns and increase absorptive capacity. To achieve higher coverage rates across the continent, and for donations to be a sustainable source of supply that can complement supply from AVAT and COVAX purchase agreements, this trend must change.

Countries need predictable and reliable supply. Having to plan at short notice and ensure uptake of doses with short shelf lives exponentially magnifies the logistical burden on health systems that are already stretched. Furthermore, ad hoc supply of this kind utilises capacity – human resources, infrastructure, cold chain – that could be directed towards long-term successful and sustainable rollout. It also dramatically increases the risks of expiry once doses with already short shelf-lives arrive in country, which may have long-term repercussions for vaccine confidence.

Donations to COVAX, AVAT, and African countries must be made in a way that allows countries to effectively mobilise domestic resources in support of rollout and enables long-term planning to increase coverage rates. We call on the international community, particularly donors and manufacturers, to commit to this effort by adhering to the following standards, beginning from 1 January 2022:

  • Quantity and predictability: Donor countries should endeavour to release donated doses in large volumes and in a predictable manner, to reduce transaction costs. We acknowledge and welcome the progress being made in this area, but note that the frequency of exceptions to this approach places increased burden on countries, AVAT and COVAX.
  • Earmarking: These doses should be unearmarked for greatest effectiveness and to support long-term planning. Earmarking makes it far more difficult to allocate supply based on equity, and to account for specific countries’ absorptive capacity. It also increases the risk that short shelf-life donations utilise countries’ cold chain capacity – capacity that is then unavailable when AVAT or COVAX are allocating doses with longer shelf lives under their own purchase agreements.
  • Shelf life: As a default, donated doses should have a minimum of 10 weeks shelf life when they arrive in-country, with limited exceptions only where recipient countries indicate willingness and ability to absorb doses with shorter shelf lives.
  • Early notice: Recipient countries need to be made aware of the availability of donated doses not less than 4 weeks before their tentative arrival in-country.
  • Response times: All stakeholders should seek to provide rapid response on essential information. This includes essential supply information from manufacturers (total volumes available for donation, shelf life, manufacturing site), confirmation of donation offer from donors, and acceptance/refusal of allocations from countries. Last minute information can further complicate processes, increasing transaction costs, reducing available shelf life and increasing risk of expiry.
  • Ancillaries: The majority of donations to-date do not include the necessary vaccination supplies such as syringes and diluent, nor do they cover freight costs -  meaning these have to be sourced separately – leading to additional costs, complexity and delay. Donated doses should be accompanied with all essential ancillaries to ensure rapid allocation and absorption.

AVAT, Africa CDC and COVAX remain committed to collaborate with donor countries, vaccine manufacturers and partners on ensuring these standards are upheld, as we continue to work together towards achieving Africa’s vaccination goals.


Notes to Editors

About African Union

The African Union (AU) is a continental body consisting of the 55 Member States that make up the countries of the African Continent. It was officially launched in 2002 as a successor to the Organisation of African Unity (OAU, 1963-1999).

About Africa CDC

Africa Centres for Disease Control and Prevention (Africa CDC), is a specialized technical institution of the African Union that strengthens the capacity and capability of Africa’s public health institutions as well as partnerships to detect and respond quickly and effectively to disease threats and outbreaks, based on data-driven interventions and programmes. Learn more at:

About the African Vaccine Acquisition Trust (AVAT)

The African Vaccine Acquisition Trust (AVAT) is a special purpose vehicle, incorporated in Mauritius. AVAT acts as a centralised purchasing agent on behalf of the African Union (AU) Member States, to secure the necessary vaccines and blended financing resources for achieving Africa’s COVID-19 vaccination strategy which targets vaccinating a minimum of 70% of Africa’s population based on a whole-of-Africa approach. AVAT was established by the COVID-19 African Vaccine Acquisition Task Team, which was set up in November 2020 by His Excellency President Cyril Ramaphosa, President of the Republic of South Africa, in his capacity as Chairperson of the African Union (AU), as a support component to the COVID-19 Immunisation Strategy that was endorsed by the AU Bureau of Heads of State and Government in August 2020. AVAT’s main partner institutions are the African Union’s Africa Centres for Disease Control and Prevention (Africa CDC), the African Export-Import Bank (Afreximbank), and the United Nations Economic Commission for Africa (ECA).


COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by CEPI, Gavi and WHO – working in partnership with UNICEF and PAHO as delivery partners, developed and developing country vaccine manufacturers, the World Bank, and others. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both high-income and lower-income countries.

v-safe COVID-19 Vaccine Pregnancy Registry

This registry collects health information from pregnant people who get vaccinated. This helps to expand vaccine safety data to further ensure vaccine safety.
Categories: C.D.C. (U.S.), Health
Syndicate content